Clinical trial
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
NCT00091832 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00091832 |
|---|---|
| Title | Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer |
| Official title | A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | Denosumab, IV Bisphosphonates |
| Enrollment | 255 |
| Start date | Sep 1, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Sep 21, 2004 |
| Last update posted | Jan 28, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: